Neuropath Core
神经病核心
基本信息
- 批准号:10262851
- 负责人:
- 金额:$ 37.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-15 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer’s disease biomarkerAnimal ModelAreaBiological MarkersBiological ModelsBiological Specimen BanksBloodBlood VesselsBrainCerebrospinal FluidCerebrumClinicalCollaborationsCollectionCommunitiesConsentConsultationsDNADNA RepositoryDataData SetDevelopmentDiagnosisDiagnosticDiseaseEducationEnrollmentEvaluationFosteringFunctional disorderGoalsHumanIndividualInternetLeadershipLiquid substanceMeasurementMeasuresMentorsMetabolicMetabolic DiseasesMethodsMicroscopyModelingMolecularMulti-Ethnic Study of AtherosclerosisNeurodegenerative DisordersOrganoidsParticipantPathologicPathologyPathway interactionsProceduresProtocols documentationResearchResearch PersonnelResourcesRiskRodentRoleSamplingScientific Advances and AccomplishmentsSenile PlaquesSpecimenSpinal PunctureTechnologyTherapeutic Human ExperimentationTherapeutic StudiesTranslational ResearchUnderrepresented PopulationsUniversitiesVascular DiseasesWashingtonbiological specimen archivesbrain volumeclinical centercohortdata managementdistributed dataeducation researchendophenotypeforesthealth disparityinnovationinter-institutionalneuropathologynext generationnonhuman primatenormal agingnovelnovel markeroperationprogramsrecruitrepositorysample collectionsymposiumtau Proteinstherapeutic targettissue biomarkerstranslational modelvascular risk factorvirtual
项目摘要
Neuropathology Core – Project Summary
The Neuropathology (NP) Core will provide unique resources to support the Wake Forest Alzheimer’s
Disease Research Center (ADRC) focus on transitions from normal aging to MCI, AD, and related disorders,
and the role of metabolic and vascular risk pathways in these transitions. The Core will foster innovative
research in all areas relevant to AD. To accomplish these goals, the Core will provide state-of-the-art
collection, storage, and distribution of brain and other biospecimens, establish neuropathological diagnoses of
decedent Clinical Core (CC) participants, and provide resources and expertise for non-human primate (NHP)
models for pivotal mechanistic and therapeutic research. The NP Core will also contribute to the ADRC theme
of health disparities with a unique program focused on increasing brain donation from underrepresented
groups (URGs). Through these activities, the NP Core will make impactful contributions to many National
Alzheimer’s Project Act (NAPA) Research Milestones, such as supporting deep, longitudinal molecular
endophenotyping of cohorts that include URGs (1A), data and sample sharing (3A, 4D), and development of
the next generation of animal models (4A, B, C).
The NP Core currently maintains a biospecimen repository of DNA, blood, and cerebrospinal fluid (CSF)
from >1,100 well-characterized participants from the ADRC and its affiliated studies. In the coming cycle, we
will continue to archive biospecimens from ADRC CC participants who have received careful metabolic and
vascular characterization. DNA, CSF and blood will be provided to NCRAD, other consortia, and individual
investigators. AD CSF biomarkers (Ab40, Ab42, tau, and p-tau181) are rigorously measured on all participants
who undergo lumbar puncture (LP), and special expertise is available for blood and CSF biomarkers of
metabolic and vascular disease. We continually assess scientific advances in identifying novel blood and CSF
biomarkers of ADRD and will implement these as the field evolves. Further, human protocols for brain, blood
and CSF collection have been applied to NHP models, creating a unique resource with which the AD research
community can conduct pivotal translational research. In the past cycle, we demonstrated that our NHP model
has neuropathologic changes similar to early AD such as amyloid plaques, AD-like CSF Ab42 profiles, cerebral
hypometabolism, and reduced brain volumes. Consultation about NHP and other models (rodent, organoid) will
be available.
In summary, through careful clinico-pathologic analysis of well characterized cohorts, unique biospecimen
repositories, and novel translational models, the NP Core will promote the WF ADRC themes, and provide an
exceptional resource to investigate underlying mechanisms, novel biomarkers, and therapeutic targets that
impact progression from normal aging to MCI and ADRD.
神经病理学核心-项目总结
神经病理学(NP)核心将提供独特的资源,以支持维克森林阿尔茨海默氏症
疾病研究中心(ADRC)专注于从正常衰老到MCI,AD和相关疾病的转变,
以及代谢和血管风险途径在这些转变中的作用。核心将促进创新
研究与AD相关的所有领域。为了实现这些目标,核心将提供最先进的
收集、储存和分发脑和其他生物标本,建立神经病理学诊断,
已故临床核心(CC)参与者,并为非人灵长类动物(NHP)提供资源和专业知识
关键机制和治疗研究的模型。NP Core还将为ADRC主题做出贡献
一个独特的计划,重点是增加来自代表性不足的大脑捐赠,
(URG)。通过这些活动,NP Core将为许多国家做出有影响力的贡献。
阿尔茨海默病项目法案(NAPA)研究里程碑,如支持深,纵向分子
包括URG(1A)、数据和样本共享(3A,4D)以及
下一代动物模型(4A、B、C)。
NP Core目前维护着一个DNA、血液和脑脊液(CSF)的生物标本库
来自ADRC及其附属研究的> 1,100名特征良好的参与者。在下一个周期,我们
将继续存档来自ADRC CC参与者的生物标本,这些参与者接受了仔细的代谢和
血管特征DNA、CSF和血液将提供给NCRAD、其他财团和个人。
investigators.对所有参与者严格测量AD CSF生物标志物(Ab 40、Ab 42、tau和p-tau 181
接受腰椎穿刺(LP)的患者,可获得血液和CSF生物标志物的特殊专业知识,
代谢和血管疾病。我们不断评估在鉴定新型血液和CSF方面的科学进展
ADRD的生物标志物,并将实施这些领域的发展。此外,人类的大脑,血液
和CSF收集已应用于NHP模型,创建了AD研究的独特资源
社区可以进行关键的转化研究。在过去的周期中,我们证明了我们的NHP模型
具有类似于早期AD的神经病理学改变,例如淀粉样斑块、AD样CSF Ab 42谱、脑
代谢减退和脑容量减少关于NHP和其他模型(啮齿动物,类器官)的咨询将
随时待命
总之,通过对特征良好的队列进行仔细的临床病理分析,
知识库和新的翻译模型,NP核心将促进WF ADRC主题,并提供一个
独特的资源,以研究潜在的机制,新的生物标志物和治疗靶点,
影响从正常老化到MCI和ADRD的进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas J Montine其他文献
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-synuclein
- DOI:
10.1186/1742-2094-4-2 - 发表时间:
2007-01-04 - 期刊:
- 影响因子:10.100
- 作者:
Jinghua Jin;Feng-Shiun Shie;Jun Liu;Yan Wang;Jeanne Davis;Aimee M Schantz;Kathleen S Montine;Thomas J Montine;Jing Zhang - 通讯作者:
Jing Zhang
Thomas J Montine的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas J Montine', 18)}}的其他基金
Project 2: Particle and brain mapping of CSF proteins using elemental reporters with mass spectrometry
项目 2:使用元素报告仪和质谱法对 CSF 蛋白进行粒子和脑图谱分析
- 批准号:
10359193 - 财政年份:2020
- 资助金额:
$ 37.48万 - 项目类别:
Project 2: Particle and brain mapping of CSF proteins using elemental reporters with mass spectrometry
项目 2:使用元素报告仪和质谱法对 CSF 蛋白进行粒子和脑图谱分析
- 批准号:
10573262 - 财政年份:2020
- 资助金额:
$ 37.48万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 37.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 37.48万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 37.48万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 37.48万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 37.48万 - 项目类别:














{{item.name}}会员




